^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSI-H/dMMR + HLA-DQB1 overexpression

    i
    Other names: HLA-DQB1, Major Histocompatibility Complex Class II DQ Beta 1, CELIAC1, HLA-DQB, IDDM1, HLA Class II Histocompatibility Antigen, DQ Beta 1 Chain, MHC Class II Antigen DQB1, MHC Class II HLA-DQ Beta Glycoprotein, MHC Class II Antigen HLA-DQ-Beta-1, MHC Class II DQ Beta Chain, MSI-H, Microsatellite instability - high, dMMR
    Entrez ID:
    3119
    Related biomarkers:
    Expression
    Mutation
    Others
    2years
    Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors. (ASCO-GI 2023)
    " We identified 1549 patients with dMMR/MSI-H CRC; 242 patients of these had received pembrolizumab or nivolumab. We identify elevated expression of HLA genes involved in formation of the MHC-II complex as a potential biomarker of improved response to immunotherapy that could, if further validated, optimize patient selection for ICI in CRC."
    Checkpoint inhibition • Clinical
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CD74 (CD74 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1)
    |
    PD-L1 expression • MSI-H/dMMR • MHC-II expression • MSI-H/dMMR + CD74 overexpression • MSI-H/dMMR + HLA-B overexpression • MSI-H/dMMR + HLA-DPA1 overexpression • MSI-H/dMMR + HLA-DQA1 overexpression • MSI-H/dMMR + HLA-DQB1 overexpression • MSI-H/dMMR + HLA-DRB1 overexpression
    |
    VENTANA PD-L1 (SP142) Assay • MI Tumor Seek™
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)